Google
CING 株価分析 — CINGULATE INC (Healthcare >> Biotechnology)
CING に関するよくある質問
CINGのROE（自己資本利益率）は？
CINGULATE INCのROEは-146.91%です。
CINGの配当利回りは？
CINGULATE INCの配当利回りは0.00%です。
CINGの品質スコア（Quality Score）は？
当社のAIはCINGの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CINGは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CINGはどのセクターに属しますか？
CINGULATE INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
CING AI Analysis Summary
Our AI summary for CING: CINGULATE INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -146.91%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.79
Price
0.03
(0.63%)
Day Change
|
|
|---|
CING, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.79 |
| PBV / Sector |
3.40 / 5.20
|
| Earning Per Share | -2.07 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
1.11 M
GREAT
|
| Average 1W Daily Value |
0.64 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:38 |
| Symbol | CING |
| Name | CINGULATE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 13.47 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 64.11 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1901 West 47th Place, Kansas City, KS, United States, 66205
Phone: 913 942 2300
Website: https://www.cingulate.com
Sector: Healthcare >> Biotechnology
Description: Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
